ArticleCancer cell international2026
MiR-181a-5p/CDK6 axis attenuates cell proliferation, migration and glycolytic reprogramming in oral squamous cell carcinoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMetabolic reprogramming is a hallmark of rapid tumor cell progression. Cellular cyclin-dependent kinase 6 (CDK6) has been reported to exhibit abnormal expression in oral squamous cell carcinoma (OSCC). However, the detailed functional role of CDK6 in OSCC glycolytic reprogramming is still unknown and requires further investigation. Studies have demonstrated that miR-181a-5p plays a significant role in the malignant progression of OSCC. Therefore, this study aimed to elucidate the molecular mechanisms underlying the role of the miR-181a-5p/CDK6 axis during glycolysis in OSCC.
methodsThe expression and functional testing of miR-181a-5p and CDK6 were conducted both in vivo and in vitro, encompassing cell proliferation, migration, and glycolysis-related metabolites. The association between miR-181a-5p expression and clinicopathological factors as well as the overall survival was analyzed. A dual-luciferase reporter assay was used to confirm the relationship between miR-181a-5p and CDK6. Quantitative real-time polymerase chain reaction(qRT-PCR) and western blotting were performed to detect gene and protein expression, respectively.
resultsCDK6 knockdown significantly inhibited OSCC cell proliferation, migration, glucose consumption, lactate, ATP production, and downregulated the expression or catalytic activities of HK2, PFKM, PKM2, LDHA, PHGDH, PSAT1, but not G6PD. Overexpressed miR-181a-5p increased overall survival (OS). CDK6 was a direct target of miR-181a-5p. CDK6 overexpression phenotypically rescued the inhibitory effect of miR-181a-5p on the proliferation, migration, and glycolytic reprogramming of OSCC cells.
conclusionsThese findings underscore the critical role of CDK6 in the OSCC progression and provide the first evidence that miR-181a-5p regulates CDK6, thereby suppressing glycolysis and the serine-glycine biosynthesis pathway (SSP) in OSCC. However, miR-181a-5p attenuates the pentose phosphate pathway (PPP) via CDK6-independent targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.